177P: Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

Authors :: Anna Polli
I. Lewis
Keith D. Wilner
Elizabeth E. Kim
Tiziana Usari
Source :: Journal of Thoracic Oncology. 11:S134
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Crizotinib
business.industry
ALK-Positive
non-small cell lung cancer (NSCLC)
medicine.disease
Internal medicine
medicine
In patient
business
medicine.drug

Full Text Access

Tools